[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Schenkman E, Lamm DL: Superficial bladder cancer therapy. ScientificWorldJournal; 2004 Jun 28;4 Suppl 1:387-99
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial bladder cancer therapy.
  • Bladder cancer treatment remains a challenge despite significant improvements in preventing disease progression and improving survival.
  • Intravesical therapy has been used in the management of superficial transitional cell carcinoma (TCC) of the urinary bladder (i.e.
  • The initial clinical stage and grade remain the main determinant factors in survival regardless of the treatment.
  • Prostatic urethral mucosal involvement with bladder cancer can be effectively treated with Bacillus Calmette-Guerin (BCG) intravesical immunotherapy.
  • Intravesical chemotherapy reduces short-term tumor recurrence by about 20%, and long-term recurrence by about 7%, but has not reduced progression or mortality.
  • Presently, BCG immunotherapy remains the most effective treatment and prophylaxis for TCC (Ta, T1, CIS) and reduces tumor recurrence, disease progression, and mortality.
  • Interferons, Keyhole-limpet hemocyanin (KLH), bropirimine and Photofrin-Photodynamic Therapy (PDT) are under investigation in the management of TCC and early results are encouraging.
  • This review highlights and summarizes the recent advances in therapy for superficial TCC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. BCG Vaccine / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Cytosine / analogs & derivatives. Cytosine / therapeutic use. Dihematoporphyrin Ether / therapeutic use. Hemocyanin / therapeutic use. Humans. Interferons / therapeutic use. Photochemotherapy. Secondary Prevention

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15349563.001).
  • [ISSN] 1537-744X
  • [Journal-full-title] TheScientificWorldJournal
  • [ISO-abbreviation] ScientificWorldJournal
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCG Vaccine; 8J337D1HZY / Cytosine; 9008-11-1 / Interferons; 9013-72-3 / Hemocyanin; 97067-70-4 / Dihematoporphyrin Ether; FV4Y0JO2CX / keyhole-limpet hemocyanin; J57CTF25XJ / bropirimine
  • [Number-of-references] 81
  •  go-up   go-down


2. Taleb A, Ismaili N, Belbaraka R, Bensouda A, Elghissassi I, Elmesbahi O, Droz JP, Errihani H: Primary lymphoma of the prostate treated with rituximab-based chemotherapy: a case report and review of the literature. Cases J; 2009;2:8875

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the prostate treated with rituximab-based chemotherapy: a case report and review of the literature.
  • In this paper we present a case of early stage non-Hodgkin lymphoma of the prostate managed with six cycles of rituximab-based chemotherapy, and review the related literature.
  • Histological and immunocytochemical studies of trans-urethral biopsy of the prostate showed diffuse large B-cell lymphoma.
  • Radiological assessment of disease confirmed the diagnosis of early stage lymphoma of the prostate.
  • He remained disease free, until now, 30 months after the end of chemotherapy.
  • CONCLUSION: According to the literature, the treatment and prognosis of primary lymphoma of the prostate is the same as that of other nodal lymphomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1988 Aug;32(2):96-8 [3400147.001]
  • [Cites] J Urol. 1985 Apr;133(4):615-6 [3981711.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1995;7(2):134 [7619764.001]
  • [Cites] J Urol. 1995 Jun;153(6):1852-4 [7752334.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1997;9(4):264-6 [9315404.001]
  • [Cites] Cases J. 2008;1(1):426 [19116013.001]
  • [Cites] J Clin Pathol. 2002 Aug;55(8):623-6 [12147660.001]
  • [Cites] Arch Pathol Lab Med. 2003 May;127(5):567-72 [12708899.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 2003 Sep;94(6):621-5 [14531272.001]
  • [Cites] Pathol Int. 2008 Mar;58(3):191-5 [18251784.001]
  • [Cites] J Cancer Res Ther. 2008 Oct-Dec;4(4):195-6 [19052394.001]
  • [Cites] Cancer Radiother. 2009 Jan;13(1):69-71 [19101192.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):732-8 [9708938.001]
  • (PMID = 20184702.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2827129
  •  go-up   go-down


3. Hori J, Kato Y, Iwata T, Taniguchi N, Hashimoto H, Yachiku S: [A case of penile malignant melanoma]. Hinyokika Kiyo; 2003 Aug;49(8):493-6
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystoscopy and urethrography revealed urethral invasion of malignant melanoma, and magnetic resonance imaging (MRI) of the penis revealed invasion to prostate, and pelvic lymph node metastases in abdominal compuled tomography (CT) but no organ metastases.
  • After these therapies, chemotherapy was performed.
  • Five months later, CT revealed multiple lung and brain metastases, and radiation therapy and chemotherapy were performed.
  • Twelve months after the operation, he died of cancer.
  • In 30 cases, stage III, IV were 20 cases and 16 cases performed operation.
  • [MeSH-major] Melanoma / secondary. Penile Neoplasms / pathology. Urethral Neoplasms / pathology
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14518390.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


Advertisement
4. Modarress M, Maghami FQ, Golnavaz M, Behtash N, Mousavi A, Khalili GR: Comparative study of chemoradiation and neoadjuvant chemotherapy effects before radical hysterectomy in stage IB-IIB bulky cervical cancer and with tumor diameter greater than 4 cm. Int J Gynecol Cancer; 2005 May-Jun;15(3):483-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative study of chemoradiation and neoadjuvant chemotherapy effects before radical hysterectomy in stage IB-IIB bulky cervical cancer and with tumor diameter greater than 4 cm.
  • Tumor size seems to be a determinant in the prognosis of early cervical cancer.
  • The purpose of this study was to compare the efficacy of preoperative combined chemoradiation and neoadjuvant chemotherapy (NAIC) programs followed by radical hysterectomy in stage IB-IIB bulky cervical cancer.
  • From September 1999 to April 2002, 60 patients with stage IB-IIB bulky cervical cancer were treated with preoperative external-beam radiotherapy to 45 Gy plus weekly cisplatin 50 mg/m2 or preoperative NAIC by cisplatin 50 mg/m2 and vincristin 1 mg/m2 every 7-10 days, for three courses.
  • Surgery was performed 4-6 weeks after the completion of the preoperative treatment.
  • There were no significant difference between age, stage, tumor size, and histopathologic type in two groups (P > 0.05).
  • Toxicity associated with two treatment methods was usually mild.
  • In chemoradiation group, two patients developed vesicovaginal fistula, and four patients developed long-term hydronephrosis that needed urethral stenting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hysterectomy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. Survival Analysis. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882173.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Kanzaki M, Seki Y, Maeda M, Miyoshi S: [A fatal case of meningeal carcinomatosis in a stage IV rectal cancer patient who had long time survival by multi- line chemotherapy]. Gan To Kagaku Ryoho; 2009 Mar;36(3):509-11
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A fatal case of meningeal carcinomatosis in a stage IV rectal cancer patient who had long time survival by multi- line chemotherapy].
  • A 65-year-old man was referred with Stage IV rectal cancer with lung and liver metastasis.
  • One month after operation, he was administered anti-cancer drugs of FOLFOX4 protocol.
  • FOLFIRI protocol started as second-line chemotherapy.
  • He was treated by urethral stenting, and FOLFOX protocol was re-started.
  • Twenty one months after operation, FOLFOX4 was stopped by drug allergy, and changed to FOLFIRI protocol.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Meningeal Carcinomatosis / drug therapy. Neoplasms, Multiple Primary / drug therapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / pathology
  • [MeSH-minor] Aged. Fatal Outcome. Humans. Male. Neoplasm Staging. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295283.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Eng TY, Naguib M, Galang T, Fuller CD: Retrospective study of the treatment of urethral cancer. Am J Clin Oncol; 2003 Dec;26(6):558-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective study of the treatment of urethral cancer.
  • Urethral cancer is rare, encompassing less than 1% of all malignancies.
  • Therefore, it is imperative to share all available information regarding urethral cancer treatment via reportage of pertinent cases, thus enabling more complete comprehension and decision-making options by both clinicians and researchers.
  • A retrospective review of 18 consecutive patients with primary urethral cancer was performed.
  • An analysis was performed of clinical stage, treatment modality, and outcome.
  • Seven of 10 patients with low-stage diagnosis remained disease free.
  • Comparatively, only one of eight patients with high-stage cancer had no apparent disease.
  • Patients with advanced cancer treated with surgery alone had a shorter disease-free survival (23.3 months) versus those treated with combination chemo/radiation therapy (45.2 months).
  • The major characteristic with prognostic impact was statistically found to be low (T1-2, N0, M0) versus high (T3-4, N1, M1) stage, as assessed by Mann-Whitney U test (z = 2.83, p = 0.0023).
  • Patients with low-stage disease exhibited increased survival with single-modality therapy.
  • However, patients with advanced cancer benefited from combined treatment using chemotherapy and radiation therapy.
  • [MeSH-major] Urethral Neoplasms / therapy

  • Genetic Alliance. consumer health - Urethral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14663371.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Gillitzer R, Hampel C, Wiesner C, Hadaschik B, Thüroff J: Single-institution experience with primary tumours of the male urethra. BJU Int; 2008 Apr;101(8):964-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Three patients had tumours of the prostatic urethra, two of which had proliferating focal inflammation and one a low-grade, superficial urothelial cancer.
  • Six patients had carcinoma of the bulbar or penile urethra, including two with previous local percutaneous radiotherapy for prostate cancer.
  • One patient had adjuvant chemotherapy after surgery.
  • Local surgical tumour control is essential for long-term survival, but the extent of surgery depends on tumour location and stage.
  • Multimodal therapy might be required to obtain an optimum oncological outcome.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Urethral Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Epidemiologic Methods. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070169.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Sopena JM, González JA, Queralt MP, Sariol JC, Redorta JP, Mavrich HV: [Metastasic urethral squamous-cell a cancer]. Actas Urol Esp; 2009 Jun;33(6):712-6
Genetic Alliance. consumer health - Urethral cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastasic urethral squamous-cell a cancer].
  • Urethral cancer is an infrequent pathology, less than 1% of the genitourinary tumors.
  • Therefore most of these tumors are locally advanced at the time of diagnosis with generally poor prognosis despite aggressive treatment.
  • Therapeutic management varies with the stage and location of the lesion.
  • Because of the rarity of this pathology, no consensus has been reached on treatment modalities, but seems to be that must be a multimodal one, including surgery, radiotherapy and chemotherapy.
  • We present the case of an 80 year-old male, with a diagnosis of urethral squamous-cell cancer, locally advanced at the time of diagnosis.
  • The patient underwent chemotherapy and radiotherapy with evidence of quick progression thereafter.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Urethral Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19711759.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


9. Segura Huerta A, Molina Saera J, Palomar Abad L, Pellín Ariño L, Guerrero Zotano A, Calderero Aragón V: [Advanced urethral carcinoma. Which is the best management of a infrequent disease?]. Actas Urol Esp; 2004 Jan;28(1):57-61
Genetic Alliance. consumer health - Best Vitelliform Macular Dystrophy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advanced urethral carcinoma. Which is the best management of a infrequent disease?].
  • Urethral cancer is an uncommon tumor (<0.1% of all genitourinary neoplasms).
  • Most of them are squamous carcinoma, adenocarcinomas are about 5% of all urethral cancer.
  • Surgery is the only curative treatment.
  • Chemotherapy (CT) and radiotherapy (RT) must be used in patients in which surgery is not possible.
  • Due to the low incidence of this neoplasm is not well established the best therapeutic approach.
  • We present the case of a female (35 years old) with a diagnosis of urethral adenocarcinoma.
  • The initial stage was IV due to non-regional lymph nodes metastases.
  • Surgery was impossible and the patient received chemotherapy and radiotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Urethral Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15046483.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


10. Dimarco DS, Dimarco CS, Zincke H, Webb MJ, Bass SE, Slezak JM, Lightner DJ: Surgical treatment for local control of female urethral carcinoma. Urol Oncol; 2004 Sep-Oct;22(5):404-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for local control of female urethral carcinoma.
  • We reviewed 53 patients (mean age 63 years) who underwent partial urethrectomy (n = 26) or radical extirpation (n = 27) for primary female urethral cancer from 1948 through 1999.
  • Clinical stage, histology, high pathologic stage (3 or 4) and grade, tumor location, nodal status, surgery type, adjuvant therapy, and treatment decade were candidate outcome predictors.
  • For adjuvant therapy, 20 patients had radiation (8 preoperatively), 2 had radiation + chemotherapy, and 1 had chemotherapy alone.
  • Of patients undergoing partial urethrectomy for pT1-3 tumors, 6/27 (22%) had urethral recurrence.
  • Recurrence-free survival +/- standard error (SE) at 10 years was 45 + 8%.
  • Those who recurred had a cancer mortality rate of 71% at 5 years postrecurrence.
  • The estimated 10-year cancer-specific survival (CSS) and crude survival (CS) rates were 60 +/- 8% and 42 +/- 7%, respectively.
  • Pathologic stage was predictive for local recurrence (P = 0.02) and CSS (P = 0.01).
  • Upon review, partial urethrectomy resulted in a high urethral recurrence rate (22%) with no bladder recurrences.
  • [MeSH-major] Carcinoma / surgery. Neoplasm Recurrence, Local. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Sex Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15464921.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Gómez Díaz ME, Castaño González-Coto D, Cuervo Calvo J, Muruamendiaraz Fernández V: [Cancer of the female urethra. Report of a new case a review of the literature]. Arch Esp Urol; 2002 Jun;55(5):568-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cancer of the female urethra. Report of a new case a review of the literature].
  • OBJECTIVE: To review the main features of female urethral cancer, the only genitourinary neoplasm with a predilection for women, the ratio being 4:1.
  • Female urethral cancer is an uncommon neoplasm that accounts for only 0.02% of all cancers found in women.
  • METHODS: A case of female urethral cancer in a 52-year-old woman is presented.
  • RESULTS/CONCLUSIONS: Female urethral cancer is an uncommon neoplasm.
  • The clinical pathologic stage is the best predictor of the disease-free survival rate.
  • For patients with Ta-2N0M0 tumors, multimodality therapy may not be required.
  • For patients with T3-4N0M0 tumors, the best results are obtained with multimodal radiation and chemotherapy with surgical resection.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Urethral Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174428.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 9
  •  go-up   go-down


12. Gschwend JE, Fair WR, Vieweg J: Radical cystectomy for invasive bladder cancer: contemporary results and remaining controversies. Eur Urol; 2000 Aug;38(2):121-30
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical cystectomy for invasive bladder cancer: contemporary results and remaining controversies.
  • The impact of stage progression of superficial cancer to invasive disease is profound.
  • However, the optimal-timed management of invasive bladder cancer is still controversial.
  • Pelvic lymph node dissection and radical cystectomy are considered to be the optimal therapy regarding local tumor control and ultimate cure of cancer, whereas chemotherapy offers the only viable but limited option for patients with distant metastasis or locally advanced disease.
  • Identification of conventional and molecular prognostic factors to predict cancer-specific survival following radical cystectomy is one important step to identify candidates that may benefit from early cystectomy or adjunct chemotherapy.
  • [MeSH-minor] Humans. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Neoplasms, Second Primary / epidemiology. Prognosis. Prostatic Neoplasms / pathology. Reproducibility of Results. Survival Rate. Urethral Neoplasms / surgery

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10895001.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] SWITZERLAND
  • [Number-of-references] 71
  •  go-up   go-down


13. Freiha F, Srinivas S: Invasive renal pelvis transitional cell carcinoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):4694

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 37 patients, 13 were ineligible (6= distal ureters; 3=non invasive cancers; 1=urethral cancer; 1=co existing lung cancer; 2=no follow up).
  • In those patients without nodal metastases, the T stage determined prognosis.
  • Adjuvant chemotherapy in this small series did not have an impact on survival.
  • The overall survival of patients with distant metastases in bladder cancer varies from 9 months to 33 months depending on the performance status and visceral metastases.
  • CONCLUSIONS: The median survival of patients with metastatic renal pelvis and upper tract tumors is worse than bladder cancer.
  • Early detection and adjuvant chemotherapy may have an impact and should be studied in larger number of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015643.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Cetina L, Rivera L, Candelaria M, de la Garza J, Dueñas-González A: Chemoradiation with gemcitabine for cervical cancer in patients with renal failure. Anticancer Drugs; 2004 Sep;15(8):761-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation with gemcitabine for cervical cancer in patients with renal failure.
  • The prognosis of cervical cancer patients with renal failure secondary to obstructive uropathy is poor.
  • Our objective was to analyze our experience in the management with chemoradiation of untreated cervical cancer patients complicated by obstructive nephropathy and kidney dysfunction.
  • Untreated patients with cervical cancer and renal failure as manifested by raised serum creatinine were treated with pelvic radiotherapy concurrently with weekly gemcitabine at 300 mg/m2.
  • Response, toxicity and renal function pre- and post-therapy were evaluated.
  • Eight FIGO stage IIIB and one IVB patients were treated.
  • Pre-treatment serum creatinine ranged from 1.6 to 18.5 mg/100 ml (median 3.3, mean 6.8) and creatinine clearance varied from 4 to 57 mg/ml/min (median 17, mean 22.1).
  • All patients had improvement in creatinine clearance (pre-therapy 22.78, post-therapy 54.3 mg/ml/min) (p=0.0058) and all but one normalized serum creatinine.
  • In this setting where cisplatin-based therapy is contraindicated, the use of gemcitabine may be considered.
  • [MeSH-major] Chemotherapy, Adjuvant / methods. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Radiotherapy, Adjuvant / methods. Renal Insufficiency / drug therapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Brachytherapy / methods. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Creatinine / blood. Drug Administration Schedule. Drug Evaluation / methods. Female. Follow-Up Studies. Humans. Injections, Intravenous. Kidney Function Tests / methods. Mexico. Middle Aged. Neoplasm Staging. Radiation-Sensitizing Agents / administration & dosage. Radiation-Sensitizing Agents / adverse effects. Radiation-Sensitizing Agents / therapeutic use. Time Factors. Treatment Outcome. Urethral Obstruction / complications

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15494637.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; AYI8EX34EU / Creatinine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


15. Izawa JI, Perrotte P, Greene GF, Scott S, Levy L, McGuire E, Madsen L, von Eschenbach AC, Pisters LL: Local tumor control with salvage cryotherapy for locally recurrent prostate cancer after external beam radiotherapy. J Urol; 2001 Mar;165(3):867-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local tumor control with salvage cryotherapy for locally recurrent prostate cancer after external beam radiotherapy.
  • PURPOSE: We identified variables associated with a positive prostate biopsy after salvage cryotherapy in patients in whom initial external beam radiotherapy for prostate cancer failed to improve our cryotherapy technique, optimize local control and improve our patient selection criteria for salvage cryotherapy.
  • We evaluated certain variables on univariate and multivariate analysis as predictors of a positive biopsy after cryotherapy, including the type of previous therapy, tumor stage and grade at initial diagnosis, prostate volume, pre-cryotherapy prostate specific antigen (PSA), number of positive biopsy cores before cryotherapy, PSA nadir after cryotherapy, stage and grade of local recurrence, number of cryoprobes, number of freeze-thaw cycles and use of a urethral warming catheter during cryotherapy.
  • Variables associated with a positive biopsy on univariate analysis were initial stage, precryotherapy PSA, PSA nadir after cryotherapy, number of cryoprobes, number of freeze-thaw cycles and a history of chemotherapy (p = 0.005, 0.027, 0.001, 0.009, 0.018 and 0.008, respectively).
  • CONCLUSIONS: Patients with initial clinical stage T1-2N0M0 disease and PSA no more than 10 ng.
  • [MeSH-minor] Biopsy. Humans. Male. Multivariate Analysis. Retrospective Studies. Salvage Therapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11176488.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


16. Sánchez-Ortiz R, Huang SF, Tamboli P, Prieto VG, Hester G, Pettaway CA: Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol; 2005 Jun;173(6):1958-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe our experience with 10 patients with penile or urethral involvement.
  • RESULTS: Of 10 patients with penile or urethral melanoma 1997 American Joint Committee on Cancer melanoma pathological stage was T1 (depth less than 0.75 mm) in 4, T2 (0.75 to 1.5 mm) in 3 and T3 (1.51 to 4 mm) in 3.
  • One patient died of melanoma that developed at a second primary site.
  • Three of the 6 patients had palpable inguinal nodes, of whom 2 died after chemotherapy for unresectable disease and 1 died of other causes 51 months after negative BILND.
  • CONCLUSIONS: Partial penectomy or WLE provided effective local control for low stage penile or urethral melanomas and all scrotal lesions.
  • Patients showing clinically positive, proven metastasis died despite appropriate surgical procedures and multi-agent chemotherapy.
  • Prophylactic modified inguinal lymphadenectomy should be considered in select patients with penile, scrotal and anterior urethral melanoma.
  • [MeSH-major] Genital Neoplasms, Male / surgery. Melanoma / surgery. Penile Neoplasms / surgery. Scrotum / surgery. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2006 Apr;175(4):1574-5; author reply 1575-6 [16516049.001]
  • (PMID = 15879790.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Lerner SP, Colen J, Shen S: Prostatic biology, histologic patterns and clinical consequences of transitional cell carcinoma. Curr Opin Urol; 2008 Sep;18(5):508-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prostatic TCC may affect prognosis independent of the primary bladder tumor stage.
  • Preoperative detection of prostatic TCC enables accurate staging and treatment planning, including assessment of the risk of cancer at the apical urethral margin and the risk of a second primary tumor of the retained urethra, all of which factor into decision-making around urinary diversion and urethrectomy.
  • Recognition of true T4a stage requires consideration of neoadjuvant chemotherapy and the need for extended pelvic and iliac lymphadenectomy in order to optimize an integrated treatment strategy.
  • SUMMARY: Prostatic involvement with TCC in patients with bladder cancer is a common event.
  • In patients with recurrent high-grade nonmuscle invasive cancer and patients undergoing radical cystoprostatectomy, a thorough assessment of the prostatic urethra and stroma is imperative for accurate staging and treatment planning.
  • [MeSH-minor] Cystectomy. Humans. Male. Urethra / pathology. Urethra / surgery. Urethral Neoplasms / secondary. Urethral Neoplasms / surgery


18. Tiguert R, Ravery V, Madjar S, Gousse AE: [Acute urinary retention secondary to clear cell adenocarcinoma of the urethra]. Prog Urol; 2001 Feb;11(1):70-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors report a case of primary clear cell cancer of the urethra in a woman presenting with acute urinary retention.
  • The diagnosis was based on cystoscopy and confirmed by histological examination of urethral biopsies.
  • Treatment consisted of urethrocystectomy with creation of an "Indiana pouch".
  • The pathological stage was T3N2M0 [1].
  • She was treated with 3 courses of chemotherapy (mitomycin and 5-fluorouracil) combined with radiotherapy.
  • This case report emphasizes the rarity of this histological type and describes the management of urinary retention in a woman when an underlying specific disease is suspected.
  • [MeSH-major] Adenocarcinoma, Clear Cell / complications. Urethral Neoplasms / complications. Urinary Retention / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11296650.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


19. Koontz BF, Lee WR: Carcinoma of the urethra: radiation oncology. Urol Clin North Am; 2010 Aug;37(3):459-66

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Urethral cancer is a rare but aggressive neoplasm.
  • Early-stage distal lesions can be successfully treated with a single modality.
  • Results for definitive radiotherapy using either or both external beam radiation therapy and brachytherapy have shown excellent cure rates in men and women.
  • Advanced tumors, however, have poor outcomes with single modality treatment.
  • Results have been improved using a combination of radiotherapy and chemotherapy, chiefly 5-fluorouracil and mitomycin C.
  • [MeSH-major] Carcinoma / radiotherapy. Urethral Neoplasms / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20674700.001).
  • [ISSN] 1558-318X
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF: Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs; 2007 Jun;25(3):265-70
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.
  • PURPOSE: The purpose of this single-center phase II study was to determine the activity of pemetrexed administered as second-line therapy in patients with advanced urothelial carcinoma.
  • METHODS: Patients with advanced urothelial carcinoma that had relapsed after receiving perioperative chemotherapy, or progressed on first-line chemotherapy for metastatic disease, were eligible for enrollment.
  • This level of activity did not meet criteria for expansion based on the pre-defined optimal 2-stage Simon design and the trial was concluded.
  • Treatment was generally well tolerated, however, 2/13 patients developed febrile neutropenia.
  • CONCLUSIONS: Pemetrexed as second-line therapy in advanced urothelial carcinoma is associated with modest activity.
  • The role of this novel antifolate in chemotherapy-naïve patients warrants further investigation.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Glutamates / therapeutic use. Guanine / analogs & derivatives. Pelvic Neoplasms / drug therapy. Salvage Therapy. Urethral Neoplasms / drug therapy. Urinary Bladder Neoplasms / drug therapy. Urothelium / pathology
  • [MeSH-minor] Administration, Oral. Drug Administration Schedule. Folic Acid / administration & dosage. Folic Acid / therapeutic use. Humans. Infusions, Intravenous. Pemetrexed. Treatment Outcome. Vitamin B 12 / administration & dosage. Vitamin B 12 / therapeutic use. Vitamin B Complex / administration & dosage. Vitamin B Complex / therapeutic use

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 18):69-75 [12571815.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1853-7 [9164195.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Mol Cancer Ther. 2002 May;1(7):545-52 [12479273.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1208-12 [9849481.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1395-401 [16622447.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3173-81 [10506615.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):589-93 [9053481.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):937-40 [11844814.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):506-13 [16773629.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1589-97 [15117980.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1627-32 [16138364.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3451-7 [16849761.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Apr;57(4):427-35 [16322992.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):552-62 [16391300.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • (PMID = 17146733.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 12001-76-2 / Vitamin B Complex; 5Z93L87A1R / Guanine; 935E97BOY8 / Folic Acid; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


21. Parekh DJ, Donat SM: Urinary diversion: options, patient selection, and outcomes. Semin Oncol; 2007 Apr;34(2):98-109
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Improved survival following radical cystectomy for bladder cancer as a result of advancements in combination chemotherapy and surgical technique has resulted in a philosophical change in the surgeon's approach to urinary diversion selection.
  • While quality of life is important, one must also consider the stage of cancer and individual patient comorbidities.
  • Which diversion provides the best local cancer control, the lowest potential for complications (short and long term), and the easiest emotional adjustment in lifestyle while still allowing the timely completion of chemotherapy and therapeutic goals?
  • We describe the three most commonly used types of diversions today, including conduits, continent cutaneous reservoirs, and orthotopic urethral diversions, as well as issues relative to patient selection and functional outcomes in patients undergoing radical cystectomy for the treatment of bladder cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17382793.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 88
  •  go-up   go-down


22. Giannarini G, Kessler TM, Thoeny HC, Nguyen DP, Meissner C, Studer UE: Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution? Eur Urol; 2010 Oct;58(4):486-94
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis of 479 patients with nonmetastatic bladder TCC receiving no neoadjuvant chemotherapy/radiation therapy and prospectively followed with a standardised protocol for a median 4.3 yr (range: 0.3-20.9) after RC at an academic tertiary referral centre.
  • MEASUREMENTS: Cancer-specific survival (CSS) and overall survival (OS) probability for asymptomatic and symptomatic recurrent patients were estimated using the Kaplan-Meier method.
  • The effects of age, nerve-sparing surgery, pathologic tumour stage, lymph node status, adjuvant chemotherapy, mode of recurrence diagnosis, and recurrence site on survival were assessed with multivariable Cox regression models.
  • Routine follow-up mostly detected lung metastases and urethral recurrences, while symptoms were predominantly the result of bone metastases and concomitant pelvic/distant recurrences.
  • Of 24 patients with urethral recurrences, 13 had carcinoma in situ (CIS).
  • Of these, 12 were successfully managed with urethra-sparing treatment, and 6 are still alive with no evidence of disease.
  • Routine follow-up appears particularly effective in early detection of urethral CIS, which can be treated conservatively.
  • [MeSH-minor] Aged. Early Detection of Cancer. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • [CommentIn] Eur Urol. 2010 Oct;58(4):495-7 [20609511.001]
  • (PMID = 20541311.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


23. Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K, Patard JJ, Kikuchi E, Montorsi F, Zigeuner R, Weizer A, Bolenz C, Koppie TM, Isbarn H, Jeldres C, Kabbani W, Remzi M, Waldert M, Wood CG, Roscigno M, Oya M, Langner C, Wolf JS, Ströbel P, Fernández M, Karakiewcz P, Shariat SF: Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol; 2010 Jun;57(6):1072-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MEASUREMENTS: Data accrued included age, gender, race, surgical approach (open vs laparoscopic), tumor pathology (stage, grade, lymph node status), tumor location, use of perioperative chemotherapy, prior endoscopic therapy, urothelial carcinoma recurrence, and mortality from urothelial carcinoma.
  • RESULTS AND LIMITATIONS: The 5-yr recurrence-free and cancer-specific survival estimates for this cohort were 75% and 78%, respectively.
  • On multivariate analysis, only pathologic tumor (pT) classification (p<0.001), grade (p<0.02), and lymph node status (p<0.001) were associated with disease recurrence and cancer-specific survival.
  • When adjusting for these variables, there was no difference in the probability of disease recurrence (hazard ratio [HR]: 1.22; p=0.133) or cancer death (HR: 1.23; p=0.25) between ureteral and renal pelvic tumors.
  • Adding tumor location to a base prognostic model for disease recurrence and cancer death that included pT stage, tumor grade, and lymph node status only improved the predictive accuracy of this model by 0.1%.
  • [MeSH-major] Carcinoma / pathology. Kidney Neoplasms / pathology. Kidney Pelvis / pathology. Ureter / pathology. Urethral Neoplasms / pathology. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • (PMID = 19619934.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


24. Matos T, Cufer T, Cervek J, Bornstnar S, Kragelj B, Zumer-Pregelj M: Prognostic factors in invasive bladder carcinoma treated by combined modality protocol (organ-sparing approach). Int J Radiat Oncol Biol Phys; 2000 Jan 15;46(2):403-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The results of bladder sparing approach for the treatment of muscle-invasive bladder cancer, using a combination of transurethral resection (TUR), chemotherapy, and radiotherapy, are encouraging.
  • The aim of our study was to find out which pretreatment characteristics influence the survival of patients treated by organ sparing approach that would enable us to identify the patients most suitable for this type of treatment.
  • METHODS AND MATERIALS: The prognostic value of different factors, such as age, gender, performance status, hemoglobin level, clinical stage, histologic grade, presence of obstructive uropathy, and completeness of TUR, has been studied in 105 patients with invasive bladder cancer, who received a bladder sparing treatment in the period from 1988 to 1995.
  • In complete responders the treatment was completed by radiotherapy (50 Gy to the bladder and 40 Gy to the regional lymph nodes), whereas nonresponders underwent cystectomy whenever feasible.
  • RESULTS: Our study has confirmed an independent prognostic value of performance status, histologic grade, and obstructive uropathy, for the disease-specific survival (DSS) of bladder cancer patients treated by a conservative approach.
  • We believe that performance status best reflects the extent of disease and exerts significant influence on the extent and course of treatment, while obstructive uropathy is a good indicator of local spread of the disease, better than clinical T-stage.
  • CONCLUSION: Patients with muscle-invasive bladder cancer who are most likely to benefit from conservative treatment approach include those with good performance status, absence of hydronephrosis, and histologic low grade transitional cell carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / therapy. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / blood. Carcinoma / pathology. Carcinoma / therapy. Combined Modality Therapy. Female. Follow-Up Studies. Hemoglobin A / analysis. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Severity of Illness Index. Sex Factors. Urethral Obstruction / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10661347.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 9034-51-9 / Hemoglobin A
  •  go-up   go-down


25. Borrell Palanca A, Chicote Pérez F, Alcalá-Santaella Casanova C, Cisnal Monsalve JM, Pastor Sempere F: [Studer-type orthotopic urinary bladder: our experience]. Arch Esp Urol; 2000 Dec;53(10):893-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Studer-type orthotopic urinary bladder: our experience].
  • METHODS: The clinical records of 6 male patients who underwent radical cystectomy for invasive bladder cancer and bladder substitution with the Studer reservoir at our hospital from January 1996 to February 2000 were reviewed.
  • RESULTS: Transitional cell carcinoma was found to be the most frequent histopathological type.
  • Distribution by grade and pathological stage showed they were all high grade infiltrating tumors localized to the bladder.
  • Four patients are free of disease, one died from metastatic disease and one patient with tumor progression and multiple lung metastases at two months' follow-up is currently on chemotherapy.
  • The mean operating time was significantly longer for this procedure than for the non-continent Bricker urinary diversion (mean 7.2 hours vs 3.5 hours, respectively).
  • The early and late postoperative complications were: incontinence for up to one month after removing the urethral catheter in three patients (two of these patients are still incontinent at two months' follow-up), wound infection in two and impotence in 6 patients.
  • CONCLUSION: Reservoir function in the medium-term is good; spontaneous urethral micturition and continence are maintained.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11213393.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


26. Das S, Tunuguntla HS: Balanitis xerotica obliterans--a review. World J Urol; 2000 Dec;18(6):382-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many cases of BXO occurring after circumcision may be cases of secondary phimosis due to BXO not being recognized at the time of surgery.
  • Biopsy of the lesions is not essential in all cases and is indicated to differentiate from penile cancer and in atypical cases.
  • Early diagnosis and treatment of BXO are very important in preventing the urological complications of the diseases such as urethral stricture.
  • Treatment of BXO depends on the anatomic location of the lesions and their extent and severity, together with the rapidity of progression of the disease process.
  • The treatment may vary from topical corticosteroids, laser vaporization in early cases to meatoplasty and urethroplasty in extensive cases.
  • Topical pharmacotherapy is useful in the early stages to reduce the initial symptoms and slow down the progression, but is not effective in all cases and is not the curative treatment of disease.
  • Meatal stenosis, phimosis, scar adhesions, fissures, erosions of glans and prepuce and involvement of the urethra are indications for surgical treatment.
  • Surgery seems to be the only treatment that can relieve the symptoms of advanced disease.
  • BXO involving anterior urethra can be treated by 2-stage urethroplasty or substitution urethroplasty.
  • The complete excision of the stricture and flap urethroplasty seems to be better than a 2-stage procedure.
  • However, at the present time, it is not possible to say that surgery can completely resolve this chronic and progressive disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11204255.001).
  • [ISSN] 0724-4983
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  • [Number-of-references] 27
  •  go-up   go-down


27. Molinié V, Longchampt E, Ouazana D, Lebret T: [Bladder tumors and molecular markers. Current status and perspectives]. Ann Pathol; 2003 Sep;23(4):306-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With 15,000 new cases each year, bladder tumors are the second leading urological cancer in France, after prostate carcinoma.
  • In spite of advances in surgical techniques and therapeutic protocols based on trans-urethral resection associated with additive treatment (immunotherapy or endovesical chemotherapy), the natural course of superficial bladder tumors remains marked by two risks: recurrence and progression.
  • In spite of the impressive efforts developed by molecular biologists searching for new specific markers, none of the markers can currently replace histological features such as stage and grade.
  • Although detection of microsatellite instability is a promising approach, numerous difficulties limit the use of these markers and prevent their application in routine practice.
  • Let us hope that the new techniques for tissue analysis such as DNA or tissue-arrays developed for simultaneous analysis of hundreds or even thousands of tumors will allow identification and validation of biological and even therapeutic markers.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Pathol. 2003 Sep;23(4):293-6 [14597893.001]
  • (PMID = 14597895.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 160
  •  go-up   go-down


28. Merrick GS, Butler WM, Wallner KE, Lief JH, Galbreath RW: Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology; 2002 Oct;60(4):650-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
  • OBJECTIVES: To evaluate the influence of prophylactic versus therapeutic alpha-blockers on urinary morbidity after permanent prostate brachytherapy.
  • Multiple clinical and treatment parameters were evaluated to identify the factors associated with acute urinary morbidity.
  • METHODS: A total of 234 consecutive patients underwent permanent prostate brachytherapy in one of two prospective randomized studies from October 1999 through February 2001 using either palladium-103 or iodine-125 for clinical Stage T1b-T2b (1997 American Joint Commission on Cancer staging system) prostate cancer at either the Schiffler Cancer Center or Puget Sound Health Care System.
  • In 142 patients, an alpha-blocker was initiated before implantation and continued at least until the International Prostate Symptom Score (IPSS) returned to baseline levels; 92 patients either did not receive an alpha-blocker or received a therapeutic alpha-blocker after implantation because of urinary obstructive symptoms.
  • The clinical and treatment parameters evaluated for urinary morbidity included prophylactic versus therapeutic alpha-blockers, age, preimplant IPSS, ultrasound volume, use of neoadjuvant hormones, use of supplemental external beam radiotherapy, isotope, urethral dose, and multiple dosimetric quality indicators (minimal dose received by 90% of the prostate gland and percentage of prostate volume receiving 100% or 200% of the prescribed minimal peripheral dose).
  • RESULTS: In both the prophylactic and the therapeutic cohorts, the IPSS peaked 1 month after implantation.
  • Of the 125 patients receiving prophylactic alpha-blockers, 102 (81.2%) remained medication dependent at the conclusion of the study, and 140 (78.2%) of 179 patients receiving alpha-blockers other than for hypertensive purposes did so.
  • Cox regression analysis revealed that only the prophylactic use of alpha-blockers and the difference between the preimplant IPSS and the 1-month IPSS were predictive of the time to return to the referent zone.
  • CONCLUSIONS: Prophylactic use of alpha-blockers results in significantly less urinary morbidity than either the absence or therapeutic use of alpha-blockers.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adrenergic alpha-Antagonists / therapeutic use. Brachytherapy / adverse effects. Postoperative Complications / drug therapy. Postoperative Complications / prevention & control. Prazosin / analogs & derivatives. Prostatic Neoplasms / radiotherapy. Urination Disorders / drug therapy. Urination Disorders / prevention & control
  • [MeSH-minor] Biopsy. Doxazosin / therapeutic use. Follow-Up Studies. Humans. Iodine Radioisotopes / therapeutic use. Male. Palladium / therapeutic use. Prostate / pathology. Prostate-Specific Antigen / blood. Radioisotopes / therapeutic use. Radiotherapy, Conformal. Sulfonamides / therapeutic use. Treatment Outcome. Urinary Retention / prevention & control

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • Hazardous Substances Data Bank. Tamsulosin .
  • Hazardous Substances Data Bank. PRAZOSIN HYDROCHLORIDE .
  • Hazardous Substances Data Bank. PALLADIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12385927.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Iodine Radioisotopes; 0 / Radioisotopes; 0 / Sulfonamides; 5TWQ1V240M / Palladium; 8L5014XET7 / Terazosin; EC 3.4.21.77 / Prostate-Specific Antigen; G3P28OML5I / tamsulosin; NW1291F1W8 / Doxazosin; XM03YJ541D / Prazosin
  •  go-up   go-down


29. Hinerman-Mulroy A, Merrick GS, Butler WM, Wallner KE, Allen Z, Adamovich E: Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys; 2004 Aug 1;59(5):1367-82
Hazardous Substances Data Bank. PALLADIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the cytoreductive consequences of neoadjuvant androgen deprivation therapy on International Prostate Symptom Score (IPSS) normalization, catheter dependency, and the need for surgical intervention secondary to bladder outlet obstruction after permanent interstitial brachytherapy.
  • METHODS AND MATERIALS: A total of 116 patients (median follow-up, 30 months) with preandrogen and postandrogen deprivation therapy ultrasound studies and no history of preimplant transurethral resection of the prostate were evaluated.
  • Androgen deprivation-induced changes in prostate volume, transition zone (TZ) volume, and urethral location were correlated with IPSS resolution, catheter dependency, and the need for postimplant surgical intervention.
  • The urethral location was determined by identification of a urinary catheter.
  • Additional clinical, treatment, and dosimetric parameters evaluated included patient age, pretreatment prostate-specific antigen, Gleason score, clinical T stage, preimplant IPSS, pre- and postandrogen deprivation ultrasound studies, treatment planning volume, supplemental external beam RT, isotope, total implant activity, Day 0 maximal dose received by 90% of the prostate gland, Day 0 percentage of prostate volume receiving 100%, 150%, and 200% of the prescribed minimal peripheral dose, and urethral dose.
  • RESULTS: For hormonally manipulated patients, the prostate volume at implantation did not have a statistical influence on the percentage of patients returning to IPSS baseline, the time for IPSS normalization, the incidence of catheter dependency, the catheter-dependency time, or the need for postimplant surgical intervention.
  • Using Cox regression analysis, the time to IPSS resolution was best predicted by the percentage of TZ volume reduction.
  • Stepwise linear regression analysis demonstrated that the catheter-dependency time was best predicted by the prehormonal therapy prostate volume, posthormonal therapy TZ volume, and the change in the urethral position; prolonged catheter dependency by the percentage of TZ volume reduction, prehormonal therapy TZ index, and the change in the urethral position; and the need for postimplant surgical intervention by the posthormonal therapy TZ index and the change in the urethral location.
  • CONCLUSION: After neoadjuvant androgen deprivation therapy for volume reduction, some brachytherapy-related urinary morbidity parameters are highly related to the preandrogen deprivation prostate volume, variants in the TZ volume, and changes in the urethral location.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Brachytherapy / adverse effects. Gonadotropin-Releasing Hormone / agonists. Prostate / drug effects. Prostatic Neoplasms / drug therapy. Urinary Bladder Neck Obstruction / etiology
  • [MeSH-minor] Analysis of Variance. Catheterization. Humans. Iodine Radioisotopes / therapeutic use. Male. Neoadjuvant Therapy. Palladium / therapeutic use. Prostate-Specific Antigen / blood. ROC Curve. Radioisotopes / therapeutic use. Regression Analysis. Urethra / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15275722.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0 / Iodine Radioisotopes; 0 / Radioisotopes; 33515-09-2 / Gonadotropin-Releasing Hormone; 5TWQ1V240M / Palladium; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


30. Nag S, Tippin D, Ruymann FB: Intraoperative high-dose-rate brachytherapy for the treatment of pediatric tumors: the Ohio State University experience. Int J Radiat Oncol Biol Phys; 2001 Nov 1;51(3):729-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative high-dose-rate brachytherapy for the treatment of pediatric tumors: the Ohio State University experience.
  • PURPOSE: To determine whether intraoperative high-dose-rate brachytherapy (IO-HDRBT) can be used to decrease the dose of external beam radiotherapy (EBRT) in the treatment of children with soft-tissue sarcomas and, thereby, reduce morbidity without compromising local control.
  • METHODS AND MATERIALS: From March 1992 through April 1999, 13 pediatric patients were treated with IO-HDRBT, low-dose EBRT, chemotherapy, and radical surgery at 21 sites that were not amenable to intraoperative electron beam therapy.
  • The IO-HDRBT dose at 5 mm depth was 10 to 12.5 Gy for close margins/microscopic disease at 14 sites and 12.5 to 15 Gy for gross disease at 7 sites.
  • The treatment volumes ranged from 4 to 96 cm(3) (mean 27).
  • The EBRT dose was limited to 27-30 Gy in most cases to minimize growth retardation and preserve normal organ function.
  • Of the 2 who died, 1 had Stage III pulmonary blastoma with a sacral recurrence; the other had Stage IV undifferentiated synovial sarcoma with a pulmonary recurrence.
  • One local failure occurred in a patient with gross residual disease after incomplete resection for Stage IV pulmonary blastoma.
  • One patient developed impaired orbital growth with mild ptosis.
  • Another patient required orthopedic pinning of her femoral subcapital epiphysis and construction of a neobladder secondary to urethral obstruction.
  • CONCLUSIONS: IO-HDRBT allowed for reduction in EBRT without compromising local control or disease-free survival in children with soft-tissue sarcomas.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Intraoperative Period. Male. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11597815.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Merrick GS, Butler WM, Wallner KE, Allen ZA, Lief JH, Hinerman-Mulroy A, Galbreath RW: The impact of prostate volume and neoadjuvant androgen-deprivation therapy on urinary function following prostate brachytherapy. Cancer J; 2004 May-Jun;10(3):181-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of prostate volume and neoadjuvant androgen-deprivation therapy on urinary function following prostate brachytherapy.
  • PURPOSE: The purpose of this article is to evaluate the impact of prostate size and the magnitude of cytoreduction after neoadjuvant androgen-deprivation therapy (ADT) on catheter dependency, urinary symptomatology, and need for postbrachytherapy surgical intervention.
  • MATERIALS AND METHODS: From February 1998 to August 2002, 186 consecutive patients under went monotherapeutic brachytherapy (no supplemental external-beam radiotherapy or ADT), and 101 consecutive patients received < or = 6 months of ADT (a luteinizing hormone-releasing hormone agonist and an anti-androgen) in conjunction with brachytherapy without supplemental external-beam radiotherapy for clinical Tlc-T2b (2002 American Joint Committee on Cancer) prostate cancer.
  • Evaluated parameters included patient age, pretreatment prostate-specific antigen, Gleason score, clinical T stage, preimplantation IPSS, ultrasound volume, hormonal status, isotope, D(90), V(100/150/200), and urethral dose (average and maximum).
  • [MeSH-major] Androgen Antagonists / therapeutic use. Brachytherapy / methods. Neoadjuvant Therapy. Prostate / pathology. Prostatic Neoplasms / radiotherapy. Urinary Tract / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15285928.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists
  •  go-up   go-down


32. Davis JW, Sheth SI, Doviak MJ, Schellhammer PF: Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. J Urol; 2002 Feb;167(2 Pt 1):494-500; discussion 501
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Intravesical bacillus Calmette-Guerin (BCG) treatment of high risk superficial bladder cancer has reduced recurrence and progression, and lengthened disease specific survival.
  • However, documentation of treatment durability is limited.
  • A total of 44 cases were carcinoma in situ plus or minus papillary and 35 were stage T1, which was assigned only if muscularis propria free of tumor was present on the biopsy specimen.
  • RESULTS: Of 98 patients with minimum followup greater than 10 years disease progressed to stage T2 or greater in 27 at a median of 30.7 months (range 1.2 to 143.7), of whom cystectomy was performed in 16, cystectomy for recurrent high risk Ta/T1 disease was required in 10, death from transitional cell carcinoma occurred in 13 at a median of 69.7 months (range 11 to 135), upper tract tumor developed in 13 at a median of 49 months (range 9 to 146) and there was evidence of prostatic urethral involvement in 21.
  • Patients must be followed closely and cystectomy recommended for those with an initial incomplete response after initial therapy or recurrent high risk disease.
  • [MeSH-major] BCG Vaccine / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11792905.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down






Advertisement